The authors said the case report provides a cautionary example for health providers in areas with low TB incidence.
The price cut for bedaquiline will enable low- and middle-income countries to buy more WHO-recommended treatment regimens for drug-resistant TB.
EU countries reported 33,527 TB cases in 2021, which continues a downward trend observed since 2002.
Scaling up preventive TB treatment for people with HIV/AIDS and household contacts of newly diagnosed TB patients could save nearly 850,000 lives by 2035, experts estimate.
The agreement between Johnson & Johnson and the Stop TB Partnership will make cheaper, generic versions of bedaquiline available in low- and middle-income nations.
The first clinical trial of a 3-month treatment regimen for tuberculosis is closing enrollment because of a high rate of unfavorable outcomes.
The Bill & Melinda Gates Foundation and Wellcome will provide $550 million for a phase 3 trial of a vaccine to prevent tuberculosis.
The pooled proportion of cases treated successfully was 44%, well below the WHO target success rate of 75%.
The authors say the oral BPaL regimen has "transformed" treatment for drug-resistant tuberculosis.
Ahead of a UN meeting, the executive director of the Stop TB Partnership discusses why the world hasn't done more to combat tuberculosis, and why she's hopeful for the future.
